Skip to main content
. 2019 Mar 19;10:271. doi: 10.3389/fphys.2019.00271

FIGURE 4.

FIGURE 4

Empagliflozin does not significantly change NCC expression, but decreases ENaC expression in diabetic rat kidneys. (A) Representative renal sections immunostained with anti-NCC. (B) Quantitative analysis of results for NCC demonstrates the increased expression of NCC in lixisenatide-treated diabetic kidneys. ∗P = 0.004 vs. LETO. †P < 0.001 vs. other groups. Magnification, ×200. (C) Representative immunoblot reacting with anti-NCC, anti-α-ENaC and anti- γ-ENaC. (D) Densitometric analysis shows that expression of NCC was significantly elevated in lixisenatide-treated OLETF rats. ∗P < 0.0001 vs. other groups. †P = 0.019 vs. LETO; P = 0.002 vs. OLETF_C. (E) Densitometric analysis shows that abundance of α-ENaC was decreased in empagliflozin-treated diabetic rats compared with normal or diabetic control groups. ∗P = 0.035 vs. LETO; P = 0.009 vs. OLETF_C. (F) On densitometric analysis, expression of γ-ENaC, increased by untreated diabetes mellitus, was significantly decreased with all treatments. ∗P < 0.001 vs. OLETF_V. †P = 0.006 vs. OLETF_E; P = 0.048 vs. OLETF_L; P < 0.001 vs. OLETF_V. n = 8 per each group.